Compare SON & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SON | TGTX |
|---|---|---|
| Founded | 1899 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.9B |
| IPO Year | 2014 | 2008 |
| Metric | SON | TGTX |
|---|---|---|
| Price | $53.19 | $27.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $63.00 | $49.80 |
| AVG Volume (30 Days) | 1.0M | ★ 1.4M |
| Earning Date | 05-20-2026 | 05-29-2026 |
| Dividend Yield | ★ 4.02% | N/A |
| EPS Growth | 510.30 | ★ 1746.67 |
| EPS | ★ 10.07 | 2.77 |
| Revenue | ★ $7,518,753,000.00 | $2,785,000.00 |
| Revenue This Year | $0.03 | $48.75 |
| Revenue Next Year | $2.01 | $25.01 |
| P/E Ratio | ★ $5.24 | $9.72 |
| Revenue Growth | ★ 41.72 | N/A |
| 52 Week Low | $38.65 | $25.37 |
| 52 Week High | $58.44 | $46.48 |
| Indicator | SON | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.58 | 37.66 |
| Support Level | $43.24 | $25.37 |
| Resistance Level | $58.44 | $32.77 |
| Average True Range (ATR) | 1.40 | 1.15 |
| MACD | -0.62 | -0.23 |
| Stochastic Oscillator | 23.57 | 13.31 |
Over its 100-year-plus history, Sonoco Products has steadily assembled a diverse portfolio of industrial and consumer packaging product offerings such as flexible and rigid plastics, reels and spools, pallets, and composite cans. The company serves a variety of consumer and industrial end markets throughout North America. Sonoco has raised its dividend each year for more than 40 years.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.